Acurx Pharmaceuticals’ (ACXP) “Buy” Rating Reiterated at HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Price Performance

Shares of NASDAQ ACXP traded down $0.03 during trading on Tuesday, reaching $1.31. 125,397 shares of the stock traded hands, compared to its average volume of 1,112,145. Acurx Pharmaceuticals has a 52-week low of $1.27 and a 52-week high of $8.34. The company has a 50-day moving average of $1.43 and a 200-day moving average of $2.08. The stock has a market capitalization of $7.26 million, a P/E ratio of -0.49 and a beta of -2.02.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). Analysts expect that Acurx Pharmaceuticals will post -2 earnings per share for the current fiscal year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.